Trials / Completed
CompletedNCT05019586
Helicobacter Pylori Resistance
Helicobacter Pylori Resistance. A Study of Morbidity, Immunological and Clinical Phenotypes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 185 (actual)
- Sponsor
- University Hospital of North Norway · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of the study was to characterize the morbidity, immunological, microbiolical and clinical phenotypes of patients with treated- resistance to Helicobacter pylori (HP) infection, and the effect of triple therapy including the levofloxacin. Control groups were newly diagnosed, previously infected and never infected HP patients
Detailed description
See Nestegard O, et al. PLOS ONE \| https://doi.org/10.1371/journal.pone.0238944 September 23, 2020
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | levofloxacin, amoxicillin, clarithromycin | Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days |
Timeline
- Start date
- 2010-04-15
- Primary completion
- 2020-07-10
- Completion
- 2020-07-10
- First posted
- 2021-08-25
- Last updated
- 2021-08-25
Source: ClinicalTrials.gov record NCT05019586. Inclusion in this directory is not an endorsement.